Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph:
Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
Claim 7 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 7 appears to have the same subject matter as claim 6 without further limiting the subject matter of claim 6. Applicant may cancel the claim, amend the claim to place the claim in proper dependent form, rewrite the claim in independent form, or present a sufficient showing that the dependent claim complies with the statutory requirements.
Claim Rejections - 35 USC § 102
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-10, 13-16 and 19-20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Yang et al. (hereafter Yang)(US PgPub 2020/0317210).
Regarding claim 1, Yang discloses a medical device (Figures 10-12), comprising: a first monitoring interface having a first housing (Figures 10, 12, Element 2110 and Paragraphs 0045-0048 where a user places their left palm on at least one of a plurality of sensing modules); a second monitoring interface having a second housing (Figures 10, 12, Elements 2110 and Paragraphs 0045-0048 where a user places their right palm on at least one of a plurality of sensing modules); the first monitoring interface and the second monitoring interface being operatively linked (Figure 10, Element 2100 and Paragraphs 0045-0046 where the sensing modules are operatively linked in the information sensing system 2100); the first housing and the second housing being configured to be biased against a steering wheel of a vehicle (Figure 12, Elements 2110 and Paragraphs 0048 where the sensing modules are biased against an interior of the steering wheel); and wherein the biased first housing and the biased second housing expose the first monitoring interface and the second monitoring interface against a palm of a subject (Figure 12 and Paragraphs 0045-0048 where the sensing modules detect physiological information from the palms of the user).
Regarding claim 2, Yang discloses wherein the first monitoring interface and the second monitoring interface are operatively linked by a subsidiary module (Figure 10, Elements 2120, 2130 and Paragraphs 0046-0047 where the sensing modules are operatively linked to a switching circuit and microcontroller).
Regarding claim 3, Yang discloses wherein the subsidiary module is coupled to the vehicle (Figures 10-12 where the physiological information sensing system is provided in a vehicle).
Regarding claim 4, Yang discloses wherein operatively associated with the first monitoring interface and the second monitoring interface, and contained in the first housing and the second housing and the subsidiary module are at least two or more physiological monitor units (Figure 10, Elements 2112, 2114 and Paragraphs 0047-0048 where the sensing modules include an ECG sensor and a PPG sensor).
Regarding claim 5, Yang discloses wherein the two or more operatively associated physiological monitor units include sensors, biomarkers, or the like, that when the first monitoring interface and the second monitoring interface have effective skin contact with the palm of a subject, the two or more physiological monitor devices sense or monitor physiological parameters (Figures 10-12 and Paragraphs 0045-0048 where physiological parameters of the user are monitored when skin contact with the palm(s) of the user is detected).
Regarding claim 6, Yang discloses wherein the two or more operatively associated physiological monitor units include sensors, biomarkers, or the like, that when the first monitoring interface and the second monitoring interfaces have effective skin contact with the palm of a subject, the two or more physiological monitor devices sense, monitor or determine a disease or disorder (Paragraphs 0033-0034 and 0045-0048 where disease and/or physiological disorders are monitored and determined).
Regarding claim 7, Yang discloses wherein the two or more operatively associated physiological monitor units include sensors, biomarkers, or the like, that when the first monitoring interface and the second monitoring interfaces have effective skin contact with the palm of a subject, the two or more physiological monitor devices sense, monitor or determine a disease or disorder (Paragraphs 0033-0034 and 0045-0048 where disease and/or physiological disorders are monitored and determined).
Regarding claim 8, Yang discloses wherein the two or more operatively associated physiological monitor units include sensors, biomarkers, or the like, that when the first monitoring interface and the second monitoring interfaces have effective skin contact with the palm of a subject, the two or more physiological monitor devices sense, monitor or determine a disease or disorder continuously and/or in real-time (Paragraphs 0026, 0033-0034 and 0045-0048 where disease and/or physiological disorders are monitored and determined in real time).
Regarding claim 9, Yang discloses wherein the two or more operatively associated physiological monitor units include sensors, biomarkers, or the like, that when the first monitoring interface and the second monitoring interface have effective skin contact with the palm of a subject, the two or more physiological monitor devices sense, monitor or determine the attention span, alertness, fitness and general wellness of the subject (Paragraphs 0026, 0029, 0033-0034 and 0045-0048 where alertness and general wellness of the user are monitored).
Regarding claim 10, Yang discloses wherein the biomarker is one or more of the group consisting of electrocardiogram (ECG); respiration rate (RR); cardiac rhythm (CR), photoplethysmography (PPG); body mass index (BMI); alkaline phosphatase (ALP); alanine transaminase (ALT); aspartate aminotransferase (AST); arterial pH (Art pH); partial pressure of oxygen (PaO.sub.2); oxygen saturation (SpO.sub.2%); partial pressure of carbon dioxide (PaCO.sub.2); red blood cell count (RBC); mean corpuscular haemoglobin concentration (MCHC); mean corpuscular haemoglobin (MCH); mean platelet volume (MPV); platelet distribution width (PDW); red cell distribution width (RDW); white blood cells (WBC); absolute neutrophil count (ANC); activated partial thromboplastin time (aPTT); partial thromboplastin time; hypoxanthine; pulse transit time (PTT); pulse; blood pressure; capillary pulse wave; arterial pulse wave and C-reactive protein (CRP) (Figure 10, Elements 2112, 2114 and Paragraphs 0047-0048 where the sensing modules include an ECG sensor and a PPG sensor).
Regarding claim 13, Yang discloses wherein the biomarker is cardiac rhythm (Paragraphs 0028, 0030 and 0031 where cardiac rhythm is determined).
Regarding claim 14, Yang discloses wherein the biomarker is pulse transit time (PTT) (Paragraph 0044 where PTT is determined).
Regarding claim 15, Yang discloses wherein the biomarker is pulse rate (Paragraph 0028 where pulse rate is determined).
Regarding claim 16, Yang discloses wherein the biomarker is blood pressure (Paragraph 0028 where blood pressure is determined).
Regarding claim 19, Yang discloses wherein a subject is monitored continuously (Paragraphs 0026, 0033-0034 and 0045-0048 where disease and/or physiological disorders are monitored and determined continuously in real time).
Regarding claim 20, Yang discloses a medical device (Figures 10-12), comprising: a monitoring interface having a housing (Figures 10, 12, Elements 2110 and Paragraphs 0045-0048 where a user places their left palm and right palms on at least one of a plurality of sensing modules); the housing being configured to be biased against a steering wheel of a vehicle (Figure 12, Elements 2110 and Paragraphs 0048 where the sensing modules are biased against an interior of the steering wheel); and wherein the biased housing exposes the monitoring interface against a palm of a subject (Figure 12 and Paragraphs 0045-0048 where the sensing modules detect physiological information from the palms of the user).
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 11-12 are rejected under 35 U.S.C. 103 as being unpatentable over Yang et al. (hereafter Yang)(US PgPub 2020/0317210) and in view of Ravishankar et al. (hereafter Ravishankar)(US PgPub 2023/0031328).
Regarding claims 11-12, Yang does not specifically disclose wherein the biomarker is a partial pressure oxygen or an oxygen saturation. In the same field of endeavor, Ravishankar discloses a system for monitoring and alerting short-term oxygen support needs for patients where physiological data is tracked using partial pressure oxygen and an oxygen saturation (Paragraph 0048).
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to provide the physiological data tracking using partial pressure oxygen and oxygen saturation of Ravishankar to the physiological determination system of Yang, motivation being to accurately detect and monitor oxygen related biomarkers which increases user and vehicle system security. Furthermore, the biomarkers were well known before the effective filing date of the claimed invention, such a modification involves routine skill in the art and would have been obvious absent of unexpected results.
Claims 17-18 are rejected under 35 U.S.C. 103 as being unpatentable over Yang et al. (hereafter Yang)(US PgPub 2020/0317210) and in view of Park et al. (hereafter Park)(US PgPub 2020/0000353).
Regarding claims 17-18, Yang does not specifically disclose wherein the first monitoring interface and the second monitoring interface sense, monitor or determine the capillary pulse wave and the arterial pulse wave, wherein the capillary pulse wave and the arterial pulse wave are determined simultaneously, sequentially or concomitantly. In the same field of endeavor, Park discloses an apparatus for measuring bioinformation where first and second sensors detect a capillary pulse wave and an arterial pulse wave sequentially (Figure 2, Elements 110, 120 and Paragraphs 0059-0063 and 0070).
It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to provide the physiological data tracking using capillary pulse wave and arterial pulse wave data sequentially of Park to the physiological determination system of Yang, motivation being to accurately detect and monitor blood related biomarkers which increases user and vehicle system security. Furthermore, the biomarkers were well known before the effective filing date of the claimed invention, such a modification involves routine skill in the art and would have been obvious absent of unexpected results.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to THOMAS D ALUNKAL whose telephone number is (571)270-1127. The examiner can normally be reached M-F 9AM-5PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, BRIAN ZIMMERMAN can be reached at 571-272-3059. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/THOMAS D ALUNKAL/Primary Examiner, Art Unit 2686